{"id":8701,"date":"2021-10-21T19:35:29","date_gmt":"2021-10-21T19:35:29","guid":{"rendered":"https:\/\/amarintech.com\/?p=8701"},"modified":"2026-05-26T16:56:36","modified_gmt":"2026-05-26T16:56:36","slug":"evaluation-of-the-adhesion-of-a-transdermal-patch-pros-cons-of-proposed-methods","status":"publish","type":"post","link":"https:\/\/amarintech.com\/es\/evaluation-of-the-adhesion-of-a-transdermal-patch-pros-cons-of-proposed-methods\/","title":{"rendered":"M\u00e9todos de evaluaci\u00f3n de adhesi\u00f3n en parches transdermales: grilla vs. relaci\u00f3n de pesos"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Correct adhesion of a transdermal patch throughout its entire wear period is not an aesthetic property \u2014 it is a drug delivery important condition. A patch that partially lifts off from the skin delivers less drug than labeled, with unpredictable pharmacokinetic consequences. For this reason, transdermal patch adhesion evaluation is now a formal regulatory requirement for generic approval, alongside bioequivalence and skin irritation\/sensitization demonstrations.<\/span><\/p>

Two quantitative methods are currently used in pivotal clinical studies to measure the percentage of patch adhesion: a template with a pre-printed grid (Method 1) and a template without a grid evaluated by the weight ratio of paper cut areas (Method 2). Both are mentioned in FDA and EMA guidance documents. Both have documented biases. The choice between them has material consequences for data precision and study risk.<\/span><\/p>

The Regulatory Framework for Adhesion Evaluation<\/b><\/h2>

Both FDA and EMA have established statistical non-inferiority criteria for patch adhesion as a formal requirement in the regulatory package for generic transdermal products. The evaluation methodologies they prescribe differ in focus:<\/span><\/p>

  • FDA uses a scoring system and compares the mean adhesion score across all evaluation timepoints throughout the wear period of the Test and Reference products.<\/span><\/li>
  • EMA primarily focuses on the percentage of adhesion at the final evaluation time of the wear period, though complementary data (adhesion histograms, percentage of patches with unacceptable adhesion) are also required.<\/span><\/li><\/ul>

    Both agencies recommend obtaining the adhesion percentage through visual inspection by trained observers or through dot-matrix templates. For patches with opaque backing layers, visual inspection presents a significant limitation: the opacity prevents direct observation of the adhesive-skin interface, requiring oblique lighting and lateral-angle observation techniques to identify detachment borders \u2014 a condition that substantially increases operator training requirements and the risk of measurement variability.<\/span><\/p>

    Method 1: Template with Grid and Ratio of Number of Squares<\/b><\/h2>

    How It Works<\/b><\/h3>

    The operator places a transparent template with the exact shape of the patch \u2014 on which a grid has been pre-printed \u2014 over the applied patch. The detached zones of the patch are transcribed onto the template. The percentage of adhesion is then calculated as:<\/span><\/p>

    % Adhesion = [1 \u2013 (Sum of squares with detachments \/ Total number of squares in grid)] \u00d7 100<\/span><\/p>

    Per guideline recommendation, any grid square that is even partially covered by a transcribed detachment is counted as fully detached \u2014 not as a fractional detachment.<\/span><\/p>

    Precision Issue: Position-Dependent Bias<\/b><\/h3>

    The most significant limitation of Method 1 is that the same detached area can yield substantially different adhesion percentages depending on where it falls on the grid. Because partial squares are counted as full squares, a detachment centered on a grid intersection generates a higher apparent detachment area than the same detachment centered within a single square. Published examples demonstrate that identical detached areas in different grid positions can yield adhesion estimates ranging from 84% to 96% \u2014 a 12 percentage point spread from a methodological artifact, not a real difference in patch performance.<\/span><\/p>

    Practical consequences of this bias:<\/span><\/p>

    • Precision increases with smaller grid squares (more total squares), but smaller squares are harder for operators to count accurately, increasing the risk of counting errors.<\/span><\/li>
    • For patches of different sizes, the grid square dimensions must be adjusted proportionally to maintain comparable measurement precision across products \u2014 requiring size-specific templates.<\/span><\/li>
    • For patches with opaque backing layers, the grid overlay makes it harder to identify and transcribe detachment borders with adequate precision.<\/span><\/li><\/ul>

      Pros of Method 1: listed as an acceptable method in FDA and EMA guidance; does not require an analytical balance or cutting equipment.<\/span><\/p>

      Method 2: Template without Grid and Ratio of Area Weights<\/b><\/h2>

      How It Works<\/b><\/h3>

      The operator places a transparent template without a grid \u2014 matching the exact shape of the patch \u2014 over the applied patch, and transcribes the detached zones. The template is then photocopied onto paper. The paper copy of the total patch area and the paper copies of each detached zone are cut out and weighed on an analytical balance. Adhesion percentage is calculated as:<\/span><\/p>

      % Adhesion = [1 \u2013 (Sum of weights of detached areas \/ Total patch area weight)] \u00d7 100<\/span><\/p>

      Precision Advantage<\/b><\/h3>

      The critical difference from Method 1: the weight ratio approach measures area continuously, not in discrete grid units. Because the measurement does not depend on grid position, the same detached area produces virtually identical adhesion estimates regardless of where it occurs on the patch. In the same example used to illustrate Method 1’s bias, Method 2 produces 96% in both positions \u2014 consistent with the actual detachment, not an artifact of grid geometry.<\/span><\/p>

      This precision advantage is particularly important for patches with irregular or multiple-zone detachments (the most common real-world presentation) and for patches with opaque backing layers, where the absence of a grid overlay allows cleaner identification and transcription of detachment borders.<\/span><\/p>

      Pros of Method 2: position-independent precision; better suited to opaque-backing patches; bias is partially self-compensating (the same operator cuts both the detached area and the total area, so systematic cutting errors partially cancel in the ratio).<\/span><\/p>

      Cons of Method 2: requires an analytical balance and cutting tools; depends on operator cutting precision; shares the template-placement bias with Method 1 (gentle placement is required to avoid accidentally re-adhering lifted sections of the patch).<\/span><\/p>

      \u00a0<\/p>

      Photo + Software: An Emerging Alternative with Regulatory Limitations<\/b><\/h2>

      FDA and EMA guidelines currently recommend photographs of the patch application site as a complement to quantitative adhesion evaluation at scheduled timepoints \u2014 not as a replacement for it. While image analysis software can provide precise area quantification and offers the operational advantage of not requiring template placement over the patch, no formal regulatory proposal has been issued to accept photo+software as a primary measurement method.<\/span><\/p>

      The main limitation driving this regulatory conservatism is opaque backing patches. Products such as buprenorphine and rotigotine patches have skin-colored or tan-colored opaque external layers. A photograph of such a patch \u2014 whether showing 100% adhesion or 50% detachment \u2014 does not provide visual contrast sufficient to distinguish the adhered from the detached portions. The detachment that would be evident on a transparent-backing patch is invisible in a photograph of an opaque one.<\/span><\/p>

      Active research and scientific discussion in regulatory forums continues on standardization of photo-based measurement conditions: object distance, camera resolution, illumination angle, counterfeit protection, method validation requirements, and product design limitations. This method remains a subject of regulatory evolution rather than an established alternative.<\/span><\/p>

      Choosing the Right Method for Your Study<\/b><\/h2>

      Method Comparison: Grid Template vs. Weight Ratio<\/b><\/p>

      Criterion<\/b><\/p><\/td>

      Method 1: Grid Template<\/b><\/p><\/td>

      Method 2: Weight Ratio (no grid)<\/b><\/p><\/td><\/tr>

      Formula<\/span><\/p><\/td>

      % Adhesion = [1 \u2013 (Squares detached \/ Total squares)] \u00d7 100<\/span><\/p><\/td>

      % Adhesion = [1 \u2013 (Weight of detached area \/ Total patch area weight)] \u00d7 100<\/span><\/p><\/td><\/tr>

      Regulatory acceptance<\/span><\/p><\/td>

      Listed as optional method in FDA\/EMA guidelines<\/span><\/p><\/td>

      Used as optional method in pivotal studies<\/span><\/p><\/td><\/tr>

      Precision: same detached area, different zone<\/span><\/p><\/td>

      Can yield significantly different results (e.g. 96% vs 84%)<\/span><\/p><\/td>

      Yields virtually identical results (e.g. 96% vs 96%)<\/span><\/p><\/td><\/tr>

      Equipment required<\/span><\/p><\/td>

      Transparent template with pre-printed grid<\/span><\/p><\/td>

      Transparent template (no grid), analytical balance, paper copies<\/span><\/p><\/td><\/tr>

      Operator training needed<\/span><\/p><\/td>

      High \u2014 counting squares, grid placement, lateral angle observation<\/span><\/p><\/td>

      High \u2014 cutting precision, template placement; bias partially compensated by ratio<\/span><\/p><\/td><\/tr>

      Opaque backing patches<\/span><\/p><\/td>

      More difficult \u2014 harder to identify and transcribe detached zones through grid<\/span><\/p><\/td>

      Better \u2014 no grid overlay; allows cleaner identification of detachment borders<\/span><\/p><\/td><\/tr>

      Grid size effect<\/span><\/p><\/td>

      Larger No. of squares = more precision but higher operator error risk<\/span><\/p><\/td>

      Not applicable \u2014 measurement is continuous<\/span><\/p><\/td><\/tr>

      Main bias source<\/span><\/p><\/td>

      Grid position effect on partial squares; template re-sticking risk<\/span><\/p><\/td>

      Cutting precision; template re-sticking risk<\/span><\/p><\/td><\/tr>

      Best suited for<\/span><\/p><\/td>

      Patches with transparent\/translucent backing<\/span><\/p><\/td>

      Patches with opaque backing; studies requiring highest precision<\/span><\/p><\/td><\/tr><\/tbody><\/table>

      \u00a0<\/p>

      The selection between Method 1 and Method 2 ultimately depends on the regulatory context of the study and the physical properties of the patch. For patches with transparent or translucent backing layers and studies conducted under FDA guidance alone, Method 1 may be operationally simpler. For patches with opaque backing layers, multi-region studies where precision is critical, or programs targeting both FDA and EMA approval, Method 2 provides a precision advantage over Method 1.<\/span><\/p>

      Both methods share the same fundamental operational requirement: template placement must be gentle and precise to avoid applying pressure that re-adheres lifted patch sections \u2014 an action that would artificially inflate the measured adhesion percentage. Operator training and standardized SOPs for template handling are non-negotiable elements of any compliant adhesion evaluation program.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

      Correct adhesion of a transdermal patch throughout its entire wear period is not an aesthetic property \u2014 it is a drug delivery important condition. A patch that partially lifts off from the skin delivers less drug than labeled, with unpredictable pharmacokinetic consequences […]<\/p>\n","protected":false},"author":1,"featured_media":5869,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50,49],"tags":[],"class_list":["post-8701","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry-challenges","category-technology"],"_links":{"self":[{"href":"https:\/\/amarintech.com\/es\/wp-json\/wp\/v2\/posts\/8701","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/amarintech.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/amarintech.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/amarintech.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/amarintech.com\/es\/wp-json\/wp\/v2\/comments?post=8701"}],"version-history":[{"count":7,"href":"https:\/\/amarintech.com\/es\/wp-json\/wp\/v2\/posts\/8701\/revisions"}],"predecessor-version":[{"id":11290,"href":"https:\/\/amarintech.com\/es\/wp-json\/wp\/v2\/posts\/8701\/revisions\/11290"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/amarintech.com\/es\/wp-json\/wp\/v2\/media\/5869"}],"wp:attachment":[{"href":"https:\/\/amarintech.com\/es\/wp-json\/wp\/v2\/media?parent=8701"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/amarintech.com\/es\/wp-json\/wp\/v2\/categories?post=8701"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/amarintech.com\/es\/wp-json\/wp\/v2\/tags?post=8701"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}